P
PepGen
Transforming the Treatment of Neuromuscular Diseases
About PepGen
PepGen is a biotechnology company focused on developing advanced nucleic acid therapeutics using its proprietary peptide technology. The company collaborates with researchers and medical institutions to address complex medical conditions, including Duchenne and Becker muscular dystrophy. Operating primarily in the biopharmaceutical market, PepGen serves healthcare providers and research organizations. Its business model involves both independent and partnered development pathways, generating revenue through research collaborations, licensing agreements, and potential future sales of therapeutic products. The company aims to revolutionize the delivery of nucleic acid-based drugs, enhancing their efficacy and reach.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2018
- Headquarters
- Boston, United States
- Listing
- IPO 2022
- Employees
- 64
- Open positions
- None listed
- Dealroom signal
- 64.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Disease, Biotech and Pharma, DT and LS, UKSU, UKSU2010, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Feb 2026 | $115M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Sep 2025 | $0 | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$88M | — |
| 2025 | $0 | — | −$88M | — |
| 2024 | $0 | — | −$92M | — |
| 2023 | $0 | — | −$84M | — |
| 2022 | $0 | — | −$68M | — |
| 2021 | $0 | — | −$27M | — |
| 2020 | $0 | — | −$1.8M | — |
Growth signals
Latest recorded traffic for PepGen is 4.7K monthly website visits, down 7.8% over the last three months. PepGen's team declined 3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Oxford Science Enterprises
Series A2 investors entered at this stage
RA Capital Management
Cure Duchenne
Series B and later14 investors entered at this stage
Deerfield
Viking Global Investors
Samsara BioCapital
Tudor Group
Adage Capital
Laurion Capital Management
Gray’s Creek Capital Partners
Frazier Healthcare Partners
Perceptive Advisors
Octagon Capital Partners
Suvretta Capital Management
Invus
Janus Henderson Investors
Monashee Investment Management
Other known investors2 additional known investors
Oxford University Innovation
University of Oxford
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PepGen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PepGen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.